Treatment of the dyslipidemia of insulin resistance.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17964916.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The increase in ischemic cardiovascular mortality and morbidity in persons with insulin resistance has been adequately documented elsewhere in this issue. Some of the most important risk factors for this increased mortality and morbidity are the lipid abnormalities, which form two out of five criteria for defining the metabolic syndrome, a definition focusing on risk factors for ischemic cardiovascular disease. This article explores the description, pathophysiology, and treatment of these atherogenic lipid abnormalities.
Medical subject headings
- Dyslipidemias
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
- Insulin Resistance
- Lipids